



Effective Date 1/15/2024
Next Review Date... 1/15/2025
Coverage Policy Number IP0313

Belumosudil

Table of Contents

Overview	1
Medical Necessity Criteria	1
Reauthorization Criteria	2
Authorization Duration	2
Conditions Not Covered.....	2
Background.....	2
References	2

Related Coverage Resources

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This policy supports medical necessity review for belumosudil (**Rezurock™**).

Receipt of sample product does not satisfy any criteria requirements for coverage.

Medical Necessity Criteria

Belumosudil (Rezurock) is considered medically necessary when the following are met:

Graft-Versus-Host Disease. Individual meets **ALL** of the following criteria:

- A. Age 12 years or older
- B. Documented diagnosis of chronic graft-versus-host disease
- C. Documentation of failure, contraindication, or intolerance to **TWO** conventional systemic treatments for chronic graft-versus-host disease (for example, methylprednisolone, Imbruvica® [ibrutinib], cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, imatinib)

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Reauthorization Criteria

Continuation of Belumosudil (Rezurock) is considered medically necessary for Graft-Versus-Host Disease when the above medical necessity criteria are met AND there is documentation of beneficial response.

Authorization Duration

Initial approval duration: up to 12 months
Reauthorization approval duration: up to 12 months

Conditions Not Covered

Any other use is considered experimental, investigational or unproven.

Background

OVERVIEW

Rezurock, a kinase inhibitor, is indicated for the treatment of patients ≥ 12 years of age with **chronic graft-versus-host disease** (GVHD) after failure of at least two prior lines of systemic therapy.¹

Guidelines

The National Comprehensive Cancer Network (NCCN) Hematopoietic Cell Transplantation (version 1.2023 – March 31, 2023) guidelines recommend Rezurock for chronic GVHD as additional therapy in conjunction with systemic corticosteroids following failure (steroid-refractory disease) to \geq two prior lines of systemic therapy.^{2,3}

References

1. Rezurock™ tablets [prescribing information]. Warrendale, PA: Kadmon; April 2023.
2. The NCCN Drugs & Biologics Compendium. © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on August 11, 2023. Search term: belumosudil.
3. The NCCN Hematopoietic Cell Transplantation Clinical Practice Guidelines in Oncology (version 1.2023 – March 31, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed August 11, 2023.

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna.